If the FDA has serious worries about this, they should explain the reasons to us, and explain what the difference between their evaluation of Duadopa and the evaluations done in Europe. We have this disease; it is OUR disease; we have some sort of right to know what is going on. Treat us like adults and have a discussion. Maybe the FDA is right to keep Duadopa away from us. But when there are no answers to our questions, we can't help but speculate - for example, is the real problem not medical but financial? Apparently for some reason this treatment costs an incredible amount of money. But would the FDA make a decision based on cost? Or have they discovered a flaw in the treatment? Or they just did not get around to looking at it because we are a low priority?
Much better if they would both listen to us and speak to us. As it is, Americans keep turning up in Europe for the treatment, to the extent that Europeans have a word for it - "neuro-tourists".